These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. Dose of contrast material in the MR imaging evaluation of central nervous system tumors. Yuh WT; Halloran JI; Mayr NA; Fisher DJ; Nguyen HD; Simonson TM J Magn Reson Imaging; 1994; 4(3):243-9. PubMed ID: 8061421 [No Abstract] [Full Text] [Related]
45. Lymphocytic adenohypophysitis: contrast-enhanced MR imaging in five cases. Ahmadi J; Meyers GS; Segall HD; Sharma OP; Hinton DR Radiology; 1995 Apr; 195(1):30-4. PubMed ID: 7892490 [TBL] [Abstract][Full Text] [Related]
46. MR of corticotropin-secreting pituitary microadenomas. Colombo N; Loli P; Vignati F; Scialfa G AJNR Am J Neuroradiol; 1994 Sep; 15(8):1591-5. PubMed ID: 7985584 [TBL] [Abstract][Full Text] [Related]
47. Magnetic resonance imaging of acoustic neuromas: the role of gadolinium-DTPA. Stack JP; Ramsden RT; Antoun NM; Lye RH; Isherwood I; Jenkins JP Br J Radiol; 1988 Sep; 61(729):800-5. PubMed ID: 3179642 [TBL] [Abstract][Full Text] [Related]
48. Bladder tumor staging: comparison of contrast-enhanced CT, T1- and T2-weighted MR imaging, dynamic gadolinium-enhanced imaging, and late gadolinium-enhanced imaging. Kim B; Semelka RC; Ascher SM; Chalpin DB; Carroll PR; Hricak H Radiology; 1994 Oct; 193(1):239-45. PubMed ID: 8090898 [TBL] [Abstract][Full Text] [Related]
49. Pituitary adenoma: correlation of half-dose gadolinium-enhanced MR imaging with surgical findings in 26 patients. Davis PC; Gokhale KA; Joseph GJ; Peterman SB; Adams DA; Tindall GT; Hudgins PA; Hoffman JC Radiology; 1991 Sep; 180(3):779-84. PubMed ID: 1871293 [TBL] [Abstract][Full Text] [Related]
50. Evaluation of adrenal masses in oncologic patients: dynamic contrast-enhanced MR vs CT. Krestin GP; Freidmann G; Fishbach R; Neufang KF; Allolio B J Comput Assist Tomogr; 1991; 15(1):104-10. PubMed ID: 1987177 [TBL] [Abstract][Full Text] [Related]
51. Dynamic MRI with slow injection of contrast material for the diagnosis of pituitary adenoma. Hayashi S; Ito K; Shimada M; Tsubuku M; Kaneko I; Kogure T; Kusama K; Nanba T; Senoh A; Tsuchida S Radiat Med; 1995; 13(4):167-70. PubMed ID: 8539442 [TBL] [Abstract][Full Text] [Related]
52. Evaluation of pituitary macroadenomas with multidetector-row CT (MDCT): comparison with MR imaging. Miki Y; Kanagaki M; Takahashi JA; Ishizu K; Nakagawa M; Yamamoto A; Fushimi Y; Okada T; Mikuni N; Kikuta K; Hashimoto N; Togashi K Neuroradiology; 2007 Apr; 49(4):327-33. PubMed ID: 17200863 [TBL] [Abstract][Full Text] [Related]
55. A clinical and histopathological study of factors affecting MRI signal intensities of pituitary adenomas. Kobayashi S; Ikeda H; Yoshimoto T Neuroradiology; 1994 May; 36(4):298-302. PubMed ID: 8065575 [TBL] [Abstract][Full Text] [Related]
56. MR imaging of optic nerve lesions: value of gadopentetate dimeglumine and fat-suppression technique. Hendrix LE; Kneeland JB; Haughton VM; Daniels DL; Szumowski J; Williams AL; Mark LP; Czervionke LF AJNR Am J Neuroradiol; 1990; 11(4):749-54. PubMed ID: 2114763 [TBL] [Abstract][Full Text] [Related]
59. Gd-DTPA-enhanced MR imaging of the brain in patients with meningitis: comparison with CT. Chang KH; Han MH; Roh JK; Kim IO; Han MC; Kim CW AJR Am J Roentgenol; 1990 Apr; 154(4):809-16. PubMed ID: 2107681 [TBL] [Abstract][Full Text] [Related]
60. MRI of pituitary adenomas: the position of the normal pituitary gland. Sumida M; Uozumi T; Mukada K; Arita K; Kurisu K; Yano T; Onda J; Satoh H; Ikawa F Neuroradiology; 1994 May; 36(4):295-7. PubMed ID: 8065574 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]